190 related articles for article (PubMed ID: 17598018)
21. Thrombin-activated thrombelastography for evaluation of thrombin interaction with thrombin inhibitors.
Taketomi T; Szlam F; Vinten-Johansen J; Levy JH; Tanaka KA
Blood Coagul Fibrinolysis; 2007 Dec; 18(8):761-7. PubMed ID: 17982317
[TBL] [Abstract][Full Text] [Related]
22. Causes of isolated prolonged activated partial thromboplastin time in an acute care general hospital.
Chng WJ; Sum C; Kuperan P
Singapore Med J; 2005 Sep; 46(9):450-6. PubMed ID: 16123828
[TBL] [Abstract][Full Text] [Related]
23. Effect of telavancin (Vibativ) on routine coagulation test results.
Gosselin R; Dager W; Roberts A; Freeman L; Gandy L; Gregg J; Dwyre D
Am J Clin Pathol; 2011 Dec; 136(6):848-54. PubMed ID: 22095369
[TBL] [Abstract][Full Text] [Related]
24. From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples.
Helin TA; Lemponen M; Hjemdahl P; Rönquist-Nii Y; Lassila R; Joutsi-Korhonen L
Thromb Res; 2015 Jul; 136(1):154-60. PubMed ID: 25981140
[TBL] [Abstract][Full Text] [Related]
25. Monitoring of the anticoagulants argatroban and lepirudin: a comparison of laboratory methods.
Ivandic B; Zorn M
Clin Appl Thromb Hemost; 2011 Oct; 17(5):549-55. PubMed ID: 20834029
[TBL] [Abstract][Full Text] [Related]
26. Influence of 8 and 24-h storage of whole blood at ambient temperature on prothrombin time, activated partial thromboplastin time, fibrinogen, thrombin time, antithrombin and D-dimer.
Kemkes-Matthes B; Fischer R; Peetz D
Blood Coagul Fibrinolysis; 2011 Apr; 22(3):215-20. PubMed ID: 21297453
[TBL] [Abstract][Full Text] [Related]
27. [Prevalence of prolonged APTT and lupus anticoagulant in autoimmune thyroid disease].
Tani Y; Morita M; Noguchi S
Rinsho Byori; 1997 Sep; 45(9):899-902. PubMed ID: 9311265
[TBL] [Abstract][Full Text] [Related]
28. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate.
Douxfils J; Dogné JM; Mullier F; Chatelain B; Rönquist-Nii Y; Malmström RE; Hjemdahl P
Thromb Haemost; 2013 Sep; 110(3):543-9. PubMed ID: 23783171
[TBL] [Abstract][Full Text] [Related]
29. The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis.
He S; Blombäck M; Bark N; Johnsson H; Wallén NH
Thromb Haemost; 2010 May; 103(5):1076-84. PubMed ID: 20216982
[TBL] [Abstract][Full Text] [Related]
30. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values.
Gosselin RC; Dager WE; King JH; Janatpour K; Mahackian K; Larkin EC; Owings JT
Am J Clin Pathol; 2004 Apr; 121(4):593-9. PubMed ID: 15080313
[TBL] [Abstract][Full Text] [Related]
31. Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing.
Gosselin RC; King JH; Janatpur KA; Dager WH; Larkin EC; Owings JT
Arch Pathol Lab Med; 2004 Oct; 128(10):1142-5. PubMed ID: 15387708
[TBL] [Abstract][Full Text] [Related]
32. [Modification of the global coagulation tests for the dog. Significance for the monitoring of heparin therapy].
Mischke R; Nolte I
Tierarztl Prax; 1991 Oct; 19(5):561-6. PubMed ID: 1759273
[TBL] [Abstract][Full Text] [Related]
33. Influence of fibrinogen degradation products on thrombin time, activated partial thromboplastin time and prothrombin time of canine plasma.
Mischke R; Wolling H
Haemostasis; 2000; 30(3):123-30. PubMed ID: 11014962
[TBL] [Abstract][Full Text] [Related]
34. Differential effects of factor IIa inhibitors on the endogenous thrombin potential.
Beilfuss A; Grandoch M; Wenzel F; Hohlfeld T; Schrör K; Weber AA
Ther Drug Monit; 2008 Dec; 30(6):740-3. PubMed ID: 18824953
[TBL] [Abstract][Full Text] [Related]
35. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery.
Taneja R; Marwaha G; Sinha P; Quantz M; Stitt L; Gao R; Subramanian S; Schaus M; Keeney M; Chin-Yee I; Murkin J
Can J Anaesth; 2009 Jul; 56(7):489-96. PubMed ID: 19408066
[TBL] [Abstract][Full Text] [Related]
36. Anticoagulant activity of captopril.
Brecher AS; Murrey SJ; Gray KD; Poulimenos JN
J Cardiovasc Pharmacol; 2008 Jan; 51(1):99-105. PubMed ID: 18209575
[TBL] [Abstract][Full Text] [Related]
37. Detection of shortened activated partial thromboplastin times: an evaluation of different commercial reagents.
Ten Boekel E; Böck M; Vrielink GJ; Liem R; Hendriks H; de Kieviet W
Thromb Res; 2007; 121(3):361-7. PubMed ID: 17568658
[TBL] [Abstract][Full Text] [Related]
38. [Is the activated partial thromboplastin time suitable for monitoring of thrombosis therapy with high-dose standard heparin?].
Hürzeler C; von Felten A
Schweiz Med Wochenschr; 1994 Apr; 124(17):712-9. PubMed ID: 8202668
[TBL] [Abstract][Full Text] [Related]
39. Comparing the prothrombin time INR versus the APTT to evaluate the coagulopathy of acute trauma.
Yuan S; Ferrell C; Chandler WL
Thromb Res; 2007; 120(1):29-37. PubMed ID: 16887171
[TBL] [Abstract][Full Text] [Related]
40. Use of the activated partial thromboplastin time for heparin monitoring.
Smythe MA; Koerber JM; Westley SJ; Nowak SN; Begle RL; Balasubramaniam M; Mattson JC
Am J Clin Pathol; 2001 Jan; 115(1):148-55. PubMed ID: 11190801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
